Carvalho Fábia Susana Ginja de, de Medeiros Inês Ambrósio, Antunes Henedina
a Gastroenterology, Hepatology and Nutrition Unit, Pediatrics Department , Hospital de Braga , Braga , Portugal.
b Life and Health Sciences Research Institute (ICVS), School of Medicine , University of Minho , Braga , Portugal.
Scand J Gastroenterol. 2017 Oct;52(10):1099-1103. doi: 10.1080/00365521.2017.1342137. Epub 2017 Jun 23.
Iron deficiency is the most common cause of anemia in children with inflammatory bowel disease, although the real prevalence is unknown. Intravenous iron is suggested as the first line treatment. This study aims to determine the prevalence of iron deficiency anemia in children with inflammatory bowel disease followed in a Pediatric Gastroenterology Unit of a tertiary center and to evaluate this unit's experience with intravenous iron.
A retrospective cohort study was designed involving children with inflammatory bowel disease followed in that unit between January 2001 and April 2016. Laboratory results were collected at the moment of diagnosis, after one-year follow-up and prior each IV iron administration performed during the study period. Anemia was defined according to World Health Organization criteria and the iron deficiency was defined using recent guidelines.
Were studied 69 patients 71% had CD and 29% UC. 50.7% were female. Mean patient age at diagnosis was 13.3 years (range 1--17 years). Prevalence of ID and IDA at diagnosis was 76.8% and 43.5%, respectively. After one year follow-up, those values decreased to 68.1% (p = .182) and 21.7% (p = .002), respectively. Hemoglobin significantly increased (p < .001). Intravenous iron was administered to 92.8% of patients. No adverse reactions were reported.
Intravenous iron is the first line in the treatment of Iron deficiency anemia in Inflammatory Bowel disease and it is safe and effective. Persistent anemia and iron deficiency are common.
缺铁是炎症性肠病患儿贫血最常见的原因，但其实际患病率尚不清楚。静脉铁剂被建议作为一线治疗方法。本研究旨在确定在一家三级中心的儿科胃肠病科就诊的炎症性肠病患儿缺铁性贫血的患病率，并评估该科室使用静脉铁剂的经验。
设计了一项回顾性队列研究，纳入2001年1月至2016年4月在该科室就诊的炎症性肠病患儿。在诊断时、随访一年后以及研究期间每次静脉注射铁剂之前收集实验室结果。贫血根据世界卫生组织标准定义，缺铁根据最新指南定义。
共研究了69例患者，其中71%患有克罗恩病，29%患有溃疡性结肠炎。50.7%为女性。诊断时患者的平均年龄为13.3岁（范围1-17岁）。诊断时缺铁和缺铁性贫血的患病率分别为76.8%和43.5%。随访一年后，这些值分别降至68.1%（p = 0.182）和21.7%（p = 0.002）。血红蛋白显著升高（p < 0.001）。92.8%的患者接受了静脉铁剂治疗。未报告不良反应。
静脉铁剂是炎症性肠病缺铁性贫血治疗的一线用药，安全有效。持续性贫血和缺铁很常见。
